These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 18221765)

  • 1. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate.
    Posadas-Herrera G; Inoue S; Fuke I; Muraki Y; Mapua CA; Khan AH; Parquet Mdel C; Manabe S; Tanishita O; Ishikawa T; Natividad FF; Okuno Y; Hasebe F; Morita K
    Vaccine; 2010 Nov; 28(50):7939-46. PubMed ID: 20933564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.
    Widman DG; Ishikawa T; Fayzulin R; Bourne N; Mason PW
    Vaccine; 2008 May; 26(22):2762-71. PubMed ID: 18423946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus.
    Yamshchikov G; Borisevich V; Kwok CW; Nistler R; Kohlmeier J; Seregin A; Chaporgina E; Benedict S; Yamshchikov V
    Vaccine; 2005 Sep; 23(39):4785-92. PubMed ID: 15939510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-structural protein 1 (NS1) antibody-based assays to differentiate West Nile (WN) virus from Japanese encephalitis virus infections in horses: effects of WN virus NS1 antibodies induced by inactivated WN vaccine.
    Kitai Y; Kondo T; Konishi E
    J Virol Methods; 2011 Jan; 171(1):123-8. PubMed ID: 20974180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.
    Ishikawa T; Widman DG; Bourne N; Konishi E; Mason PW
    Vaccine; 2008 May; 26(22):2772-81. PubMed ID: 18433947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows.
    Imoto J; Ishikawa T; Yamanaka A; Konishi M; Murakami K; Shibahara T; Kubo M; Lim CK; Hamano M; Takasaki T; Kurane I; Udagawa H; Mukuta Y; Konishi E
    Vaccine; 2010 Oct; 28(46):7373-80. PubMed ID: 20851083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives.
    Seregin A; Nistler R; Borisevich V; Yamshchikov G; Chaporgina E; Kwok CW; Yamshchikov V
    Virology; 2006 Dec 5-20; 356(1-2):115-25. PubMed ID: 16935318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
    Imoto J; Konishi E
    Vaccine; 2007 Jan; 25(6):1076-84. PubMed ID: 17084490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.
    Widman DG; Ishikawa T; Winkelmann ER; Infante E; Bourne N; Mason PW
    Vaccine; 2009 Sep; 27(41):5550-3. PubMed ID: 19635608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
    Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
    J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.